Breast cancer (BC)
is the most diffused cancer type in women and
the second leading cause of death among the female population. Effective
strategies to fight estrogen responsive (ER+) BC, which represents
70% of all BC cases, rely on estrogen deprivation, via the inhibition
of the aromatase enzyme, or the modulation of its cognate estrogen
receptor. Current clinical therapies significantly increased patient
survival time. Nevertheless, the onset of resistance in metastatic
BC patients undergoing prolonged treatments is becoming a current
clinical challenge, urgently demanding to devise innovative strategies.
In this context, here we designed, synthesized, and performed in vitro
inhibitory tests on the aromatase enzyme and distinct ER+/ER–
BC cell line types of novel azole bridged xanthones. These compounds
are active in the low μM range and behave as dual-mode inhibitors,
targeting both the orthosteric and the allosteric sites of the enzyme
placed along one access channel. Classical and quantum-classical molecular
dynamics simulations of the new compounds, as compared with selected
steroidal and nonsteroidal inhibitors, provide a rationale to the
observed inhibitory potency and supply the guidelines to boost the
activity of inhibitors able to exploit coordination to iron and occupation
of the access channel to modulate estrogen production.